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ABSTRACT 19 
Antimicrobial usage in food animals has a direct impact on human health, and 20 
approximately 80% of the antibiotics prescribed in the dairy industry are used to treat 21 
bovine mastitis. Here, we provide a longitudinal description of the changes in the 22 
microbiome of milk that are associated with mastitis and antimicrobial therapy. Next-23 
generation sequencing, 16S rRNA gene quantitative real-time PCR, and aerobic 24 
culturing were applied to assess the effect of disease and antibiotic therapy on the milk 25 
microbiome. Cows diagnosed with clinical mastitis associated with Gram-negative 26 
pathogens or negative aerobic culture were randomly allocated into 5 days of Ceftiofur 27 
intramammary treatment or remained as untreated controls. Serial milk samples were 28 
collected from the affected quarter and the ipsilateral healthy quarter of the same 29 
animal. Milk from the mastitic quarter had a higher bacterial load and reduced microbial 30 
diversity compared to healthy milk. Resolution of the disease was accompanied by 31 
increases in diversity indexes and a decrease in pathogen relative abundance. 32 
Escherichia coli-associated mastitic milk samples had a remarkably distinct bacterial 33 
profile, dominated by Enterobacteriaceae, when compared to healthy milk. However, no 34 
differences were observed in culture-negative mastitis samples when compared to 35 
healthy milk. Antimicrobial treatment had no significant effect on clinical cure, 36 
bacteriological cure, pathogen clearance rate or bacterial load. 37 
  38 
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INTRODUCTION 39 
Production of animal protein to support the world’s growing human population is 40 
one of the main challenges facing humankind. Concerns related to food safety and 41 
development of antimicrobial resistance may lead to decreased availability of antibiotics 42 
for use in food animals and thereby limit our ability to control disease in agricultural 43 
animal species. Such a change in antibiotic usage in food animals could also alter 44 
perspectives on food security as it relates to public health concerns regarding antibiotic 45 
use in food animals. Thus, in-depth understanding of disease mechanisms is critical to 46 
promote animal health and at the same time encourage judicious use of antibiotics in 47 
livestock. Mastitis is one of the most common diseases in dairy herds, and 48 
approximately 20% to 30% of dairy cows develop clinical mastitis at least once during 49 
lactation 1,2. Not surprisingly, prophylaxis and treatment of mastitic cows are the major 50 
reasons for antibiotic usage in dairy farms 3,4.  51 
Maternal milk harbors a rich microbial community that is vital for establishment of 52 
the gut microbiome and immune tolerance in neonates 5,6. The same microbial 53 
community in the mammary gland may provide an environment that aids the host in 54 
preventing mammary infections. For instance, commensal bacteria present in human 55 
milk inhibit proliferation of Staphylococcus aureus7, which is also a pathogen commonly 56 
associated with mastitis in dairy cows 8. Considering that mastitis possibly reflects a 57 
dysbiosis within the mammary gland9-11, a detailed assessment of the milk microbiome 58 
during active stages of clinical disease, spontaneous recovery, treatment and post-59 
treatment is essential to further elucidate this pathological condition. 60 
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The multifactorial etiology of mastitis presents a major challenge for disease 61 
prevention and treatment of affected animals. Implementation of programs for mastitis 62 
control has reduced the prevalence of important contagious pathogens, and 63 
approximately 40% of clinical cases of mastitis are associated with opportunistic Gram-64 
negative bacteria such as Escherichia coli, Klebsiella spp., Pseudomonas spp., and 65 
Pasteurella spp. 8,12,13. Although current guidelines do not recommend the use of 66 
intramammary antibiotics for cows diagnosed with Gram-negative mastitis 3,14, improved 67 
bacteriological and clinical outcomes have been shown in mastitic cows treated with 68 
third-generation cephalosporins compared with other antimicrobials or untreated 69 
controls 15,16. However, the impact of these broad-spectrum antibiotics on the milk 70 
microbiota (other than major pathogens) remains unknown. In fact, currently, no data 71 
concerning the effect of antibiotic therapy on the mammary microbiota are available in 72 
either humans or animals. Routine methods used to assess responses to intramammary 73 
treatments overlook numerous microorganisms, which is supported by the fact that 40% 74 
of milk samples collected from cows with clinical mastitis yield negative results by 75 
aerobic culture 13. Later-generation cephalosporins have broad-spectrum antibacterial 76 
activity, so their use could unintentionally disrupt general mammary microbial 77 
populations and also increase the risk of antimicrobial resistance if not used in a 78 
judicious manner 17. Understanding the dynamics of the mammary microbiota upon 79 
antibiotic therapy is essential not only for development of effective treatment strategies, 80 
but also to facilitate the process of restoring a healthy mammary microbiota. 81 
State-of-the-art technologies have allowed the investigation of microbial 82 
communities in milk without some of the limitations imposed by culture methods 9,18,19. 83 
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Therefore, the specific objectives of the present study were: 1) to use high-throughput 84 
DNA sequencing to describe the microbiome of milk in dairy cows affected by clinical 85 
mastitis associated with Gram-negative bacteria or negative culture; 2) to determine the 86 
bacterial load based on PCR quantification of 16S rRNA gene copies, and compare 87 
microbial populations of affected and healthy quarters; and 3) to assess the effect of 88 
intramammary treatment with ceftiofur hydrochloride on the milk microbiome, bacterial 89 
load, and clinical cure in quarters affected with clinical mastitis.  90 
 91 
METHODS 92 
Ethics Statement 93 
The research protocol was reviewed and approved by the Cornell University 94 
Institutional Animal Care and Use Committee (protocol number 2013-0056). The 95 
methods were carried out in accordance with the approved guidelines. 96 
 97 
Animals, Enrollment Criteria, and Treatments 98 
Milk samples were collected from lactating Holstein cows diagnosed with clinical 99 
mastitis between April and June, 2014. All cows were housed in a single herd located in 100 
upstate New York which milked approximately 2,800 cows thrice daily during the 101 
experimental period. Clinical mastitis was defined as the presence of at least visually 102 
abnormal milk (i.e. presence of flakes, clots, or serous milk) during forestripping 103 
performed at the milking parlor. Once mastitis was diagnosed, the initial milk sample for 104 
mastitis pathogen identification was collected by trained farm personnel according to 105 
National Mastitis Council guidelines. These samples were defined as day 0 samples. 106 
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Teats were cleaned and disinfected using 70% ethanol (v/v), the initial three streams 107 
were discarded, and approximately 5 mL of milk was collected into a sterile plastic tube 108 
without preservative (Corning Life Sciences, Tewksbury, MA). Milk samples were 109 
cultured using an on-farm chromogenic culture system for fast identification of causal 110 
agents (Accumast®, FERA Animal Health LCC, Ithaca, NY) according to the 111 
manufacturer’s recommendations, and then submitted for analysis at the Quality Milk 112 
Production Services laboratory (QMPS; Cornell University, Ithaca, NY) to ensure the 113 
accuracy of on-farm culture. Disagreement between methods was observed in only two 114 
samples, which were excluded from further analyses after the results from QMPS were 115 
received. 116 
Cows diagnosed with clinical mastitis associated with Gram-negative bacteria or 117 
negative on-farm culture and that had not been treated with intramammary 118 
antimicrobials in the 14 days preceding diagnosis were deemed eligible for enrollment. 119 
On study day 1, eligible cows were randomly allocated into one of two treatments based 120 
on a list of numbers generated using the RAND function of Excel (Microsoft, Redmond, 121 
WA), blocked by aerobic culture results. Clinical score was assessed on days 1, 8, 10 122 
and 14 according to Wenz et al 20,21. Milk appearance, mammary gland appearance and 123 
systemic signs of disease (i.e. rectal temperature ≥ 39.5 ºC, dehydration and 124 
depression) were evaluated for classification of clinical score. A clinical score of ‘mild’ 125 
was assigned if only abnormal milk was observed. A ‘moderate’ score was assigned 126 
when abnormal milk and inflammation of the mammary gland were present. A ‘severe’ 127 
score was assigned if abnormal milk, local inflammation and one or more of the 128 
systemic signs of the disease were observed. 129 
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Cows assigned to the treatment group received daily intramammary infusions 130 
containing 125 mg of ceftiofur equivalents (as ceftiofur hydrochloride; Spectramast LC®, 131 
Zoetis, Florham Park, NJ) only on the mastitic quarter for five consecutive days, 132 
whereas those assigned to the control group did not receive intramammary therapy. 133 
 134 
Sample and Data Collection 135 
Serial milk samples were collected by a trained veterinarian member of the 136 
research team from each cow on study days 1, 2, 3, 4, 5, 8, 10, and 14, from both the 137 
mastitic quarter and the ipsilateral healthy quarter of the same cow. For cows in the 138 
treated group, sampling on days 1 through 5 was performed after milk out of the quarter 139 
in untreated cows, whereas treated cows were sampled immediately before 140 
intramammary treatments were applied. Teats were disinfected as described above and 141 
10 mL of milk was harvested from each quarter into a sterile plastic tube without 142 
preservative (Corning Life Sciences, Tewksbury, MA). Samples were immediately 143 
refrigerated at 4 ºC, transported to the laboratory on ice, and frozen at -20 ºC until 144 
assayed. Milk samples collected from mastitic quarters on days 10 and 14 were 145 
submitted to the QMPS laboratory for bacterial identification using standard aerobic 146 
culture. 147 
Clinical cure was defined as cows without any clinical signs on both day 10 and 148 
day 14. Bacteriological cure was defined as both the samples taken on day 10 and day 149 
14 being negative for the organism present on day 0. In all other cases the quarter was 150 
considered to be a non-cure or treatment failure. Bacteriological cure can only be 151 
evaluated in quarters that were culture positive on day 0. 152 
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DNA Isolation and Purification 153 
Milk samples were thawed, homogenized by inverting the tubes, and a 6-mL 154 
aliquot was taken for DNA isolation and purification. Milk samples were centrifuged at 4 155 
ºC and 16,100 × g for 3 minutes and the supernatant was discarded. Genomic DNA was 156 
isolated from the remaining pellet using a commercially available kit (PowerFood DNA 157 
Isolation Kit, MO BIO Laboratories Inc., Carlsbad, CA) as described previously 22. 158 
Concentration and purity of isolated DNA were evaluated based on optical density at 159 
230, 260 and 280 nm wavelengths (NanoDrop ND-1000, NanoDrop Technologies, 160 
Wilmington, DE). 161 
 162 
Amplification of the V4 Hypervariable Region of the Bacterial 16S rRNA Gene, 163 
Library Preparation, and 16S rRNA Gene Sequencing 164 
The V4 hypervariable region of the bacterial 16S rRNA gene was amplified from 165 
genomic DNA by PCR utilizing the primers 515F and 806R optimized for the Illumina 166 
MiSeq platform (Illumina Inc., San Diego, CA) 23 as described previously 24. 167 
 Equimolar libraries were sequenced in six runs using the MiSeq reagent kit V2 168 
for 300 cycles on the MiSeq platform (Illumina). Each run included 279 samples and a 169 
sequencing control that consisted of the purified barcoded PCR product of DNA 170 
extracted from Staphylococcus aureus (ATCC 25923). Gene sequences were 171 
processed using the 16S Metagenomics workflow in the MiSeq Reporter analysis 172 
software version 2.5 based on quality scores generated by real-time analysis during the 173 
sequencing run. Quality-filtered indexed reads were demultiplexed for generation of 174 
individual FASTQ files and aligned using the banded Smith-Waterman method of the 175 
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Illumina-curated version of the Greengenes database for taxonomic classification of milk 176 
microbes. Resulting FASTQ files were uploaded into the open-source pipeline 177 
Quantitative Insights into Microbial Ecology (QIIME) version 1.9.1 25. Sequences were 178 
filtered based on quality as described previously 26 and assigned to operational 179 
taxonomic units (OTUs) with 97% identity using UCLUST 27. The OTU database was 180 
rarefied using the command single_rarefaction.py from QIIME and the number of OTUs, 181 
as well as Chao1 and Shannon indexes, was calculated for each sample at a 182 
rarefication level of 5,000 reads per sample. 183 
Quantification of 16S rRNA Copies by qPCR 184 
The number of 16S rRNA copies was used as a proxy to determine bacterial load 185 
in milk samples collected on days 1, 3, 8 and 14. 16S rRNA gene copies were 186 
quantified by qPCR as described previously 28. Reactions were performed using Unibac 187 
primers (forward: 5′-TGG AGC ATG TGG TTT AAT TCG A-3′; reverse: 5′-TGC GGG 188 
ACT TAA CCC AAC A-3′; 50 pmol/reaction), 1X iQTM SYBR® Green Mastermix (Bio-189 
Rad Laboratories, Hercules, CA), and 1.5 µL of sample DNA. A standard curve was 190 
built using plasmid DNA quantified by spectrophotometry. All samples were assayed in 191 
duplicate using an iQTM5 Real-time PCR system (Bio-Rad Laboratories, Hercules, CA) 192 
set to perform denaturation at 95 ºC for 3 minutes, then 40 cycles of amplification (95 ºC 193 
for 10 seconds and 55 ºC for 30 seconds), one cycle at 95 ºC for 60 seconds, one cycle 194 
at 55 ºC for 60 seconds, and a melting curve determination.  195 
 196 
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Statistical Analyses 197 
Descriptive analyses on sequencing results were performed using the 198 
UNIVARIATE procedure of SAS version 9.3 (SAS Institute Inc., Cary, NC). Differences 199 
in the relative abundance of bacteria between quarters with clinical mastitis and healthy 200 
counterparts were evaluated at the phylum and family levels using JMP Pro 11 (SAS 201 
Institute Inc., Cary, NC). Cows were categorized according to the main pathogen 202 
identified on samples taken on study day 0 through standard culture methods into four 203 
groups, namely E. coli, Klebsiella spp., Pseudomonas spp., and negative culture. Within 204 
each group, the effect of clinical mastitis on the relative abundance of each of the ten 205 
most prevalent phyla was evaluated by ANOVA. The prevalences of all remaining phyla 206 
were combined into a single cluster. The fixed effect of disease (healthy vs. mastitic 207 
quarters) was included in the statistical models as an independent variable. Response 208 
screening was performed to assess the effect of clinical mastitis on the relative 209 
abundance of the 100 most prevalent families in each pathogen group. P-values were 210 
adjusted for false discovery rate (FDR 29) and presented as FDR LogWorth (i.e. -log10P). 211 
The mean relative abundance for each family observed across all healthy quarters was 212 
used as a reference for calculation of fold-changes. 213 
Microbiome changes occurring over time and in response to intramammary 214 
antibiotic therapy were described for the 25 most prevalent families in each pathogen 215 
group using the tabulate function of JMP Pro 11. Relative abundances of all remaining 216 
families were combined into a single cluster. The magnitude of change was scaled 217 
uniformly within health status (healthy vs. mastitic quarters). The relative abundances of 218 
major pathogens associated with clinical mastitis were evaluated within pathogen 219 
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groups by ANOVA for repeated measures using the GLIMMIX procedure of SAS. 220 
Outcomes were the relative abundance of each pathogen and the explanatory variables 221 
were treatment, time, health status (healthy vs mastitic quarter) and their two- and 222 
three-way interactions. Cow was considered a random effect in all statistical models. 223 
Time changes in the number of OTUs, Chao1 index, and Shannon index were analyzed 224 
by ANOVA for repeated measures using the GLIMMIX procedure of SAS. Within each 225 
pathogen group, two statistical models were built to evaluate the effects of mastitis (i.e. 226 
fixed effects of mastitis, time, and interaction between mastitis and time) and treatment 227 
(i.e. fixed effects of treatment, mastitis, time, and all two- and three-way interactions).  228 
The effect of cure on the relative abundance of Enterobacteriaceae family 229 
members and the Shannon diversity index was evaluated between cured and non-cured 230 
cows with clinical mastitis associated with E. coli by ANOVA for repeated measures 231 
using the Fit Model function on JMP Pro 11. Tests for normality of residuals and 232 
homogeneity of variances were conducted for each dependent variable, and data that 233 
did not fulfill ANOVA assumptions were transformed accordingly (i.e. 16S rRNA gene 234 
copy numbers). The covariance structure with the smallest Schwarz’s Bayesian 235 
information criterion value was selected for each analysis. Differences with P ≤ 0.05 236 
were considered significant and those with 0.05 < P ≤ 0.10 were considered tendencies. 237 
Results are presented as average and standard deviation (i.e. descriptive analyses of 238 
sequencing results) or least square means followed by the respective standard error of 239 
the mean. 240 
Multivariate analysis of microbiome data was carried out in R (R Core Team, 241 
Vienna, Austria)30 and QIIME. Beta diversity was analyzed through analysis of 242 
12 
 
similarities (ANOSIM) using non-rarefied data normalized employing the packages 243 
metagenomeSeq31 and vegan32 in R. Principal coordinate analysis (PCoA) was 244 
performed using weighted Unifrac distances calculated in QIIME and visualized through 245 
EMPeror33. 246 
RESULTS  247 
Clinical and Bacteriological Cure 248 
Intramammary treatment with ceftiofur hydrochloride did not significantly improve 249 
clinical and bacteriological cures of clinical mastitis compared with untreated controls 250 
(Table 1). Of the 40 cows enrolled in the control group, 75% (n=30) experienced clinical 251 
cure, whereas of the 40 cows that received intramammary antibiotic therapy, 77.5% 252 
(n=31) experienced clinical cure (P-value = 0.79). Clinical cures for cows affected with 253 
Gram-negative intramammary infections also did not differ between the treated (75% 254 
cure rate) and control cows (73.9% cure rate) (P-value = 0.93). Bacteriological cure 255 
followed the same pattern as for clinical cure, with 82.6% of the milk samples collected 256 
from non-treated mastitic quarters being negative on days 10 and 14 for the organism 257 
present on day 0, whereas in the treated group, 79.2% of the samples were considered 258 
to be bacteriological cures (P-value = 1.00). Bacteriological cure was not altered by 259 
treatment when the data were stratified and analyzed by each pathogen group (Table 260 
1). 261 
Real-time PCR Results  262 
Cows diagnosed with clinical mastitis caused by E. coli had a significantly 263 
(P=0.008) lower number of 16S rRNA gene copies in healthy quarters compared to 264 
mastitic ones on day 3 post diagnosis; however, no difference was observed in the 265 
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bacterial load as measured in 16S rRNA gene copies between healthy and mastitic 266 
quarters at days 8 and 14. Intramammary treatment with Ceftiofur caused a significant 267 
decrease in the bacterial load of mastitic quarters on day 3 (P = 0.01) compared to non-268 
treated mastitic quarters. Nonetheless, a treatment effect was no longer observed at 269 
study day 8 (Fig. 1a). 270 
In animals diagnosed with clinical mastitis yielding no bacterial growth upon 271 
aerobic culture, the number of 16S rRNA gene copies was higher in mastitic quarters 272 
compared to healthy ones. No treatment effect was observed on the bacterial load in 273 
this group of animals. Mastitic and healthy quarters exhibited the same bacterial load by 274 
study day 14 (Fig. 1c). 275 
Sequencing Results  276 
Quality-filtered reads were demultiplexed and a total of 67,413,334 sequences 277 
was used for downstream analyses (mean=47,241.3 ± SD=32,625.0 reads/sample). 278 
The median length for all reads was 301 bp.  279 
Microbiome Changes Associated With Clinical Mastitis 280 
The mean relative abundance of bacteria from the phylum Proteobacteria was 281 
greater (P < 0.01) in the milk from mastitic quarters infected by E. coli and 282 
Pseudomonas spp. compared with that of healthy quarters (Fig. 2a-b). This was driven 283 
mostly by greater abundances of Enterobacteriaceae (P < 0.001; Fig. 3) and 284 
Pseudomonadaceae (P = 0.03; Fig. S1). On the other hand, the average abundance of 285 
Firmicutes, Actinobacteria, Bacteroidetes, Tenericutes, Chlorobi, and the combination of 286 
all remaining phyla was greater (P < 0.05) in healthy compared with mastitic quarters 287 
infected by E. coli (Fig. 2a). A similar pattern was observed in cows with clinical mastitis 288 
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associated with Pseudomonas spp. (n = 2 quarters), in which the abundance of 289 
Actinobacteria and Bacteroidetes was greater (P < 0.05) and that of Chlorobi tended to 290 
be greater (P = 0.08) in healthy compared with mastitic quarters (Fig. 2b). The diversity 291 
of milk microbial populations was reduced (P < 0.0001) in E. coli mastitis compared with 292 
healthy quarters (Fig. 1b). The Shannon index was also influenced (P < 0.0001) by the 293 
interaction between mastitis and time, as values increased from day 1 through 14 in 294 
mastitic quarters, whereas no change was observed in healthy counterparts (Fig. 1b). 295 
Likewise, the richness of microbial communities was reduced in E. coli mastitis 296 
compared with healthy quarters (Fig. S2 a). 297 
The relative abundances of Firmicutes (P = 0.06) and the remaining phyla (P = 298 
0.02) were greater in healthy quarters compared with those infected by Klebsiella spp. 299 
(Fig. 2c). Nevertheless, mastitis did not affect the relative abundances of other phyla or 300 
individual families (Fig. S3). Clinical mastitis associated with Klebsiella spp. had 301 
reduced (P = 0.05) Shannon values shortly after diagnosis but had no effect on the 302 
Chao1 index (Fig. S4 a-b). 303 
Shifts in the milk microbiome were less pronounced in cases of clinical mastitis 304 
associated with a negative aerobic culture (Fig. 2d). The relative abundance of 305 
Firmicutes was higher (P = 0.08), whereas those of Bacterioidetes (P = 0.06), 306 
Tenericutes (P = 0.05), Spirochaetes (P = 0.01), and the combined remaining phyla (P = 307 
0.08) were lower in mastitic quarters. Fluctuations in bacterial communities were not 308 
associated with specific families (Fig. 4). Nevertheless, diversity was reduced (P < 0.01) 309 
in mastitic compared with healthy quarters (Fig. 1d). The same trend was observed in 310 
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the Chao1 richness index on the first two days after diagnosis of clinical mastitis (Fig. 311 
S2 b). 312 
Effect of Intramammary Antibiotic Therapy on the Milk Microbiome 313 
In cows diagnosed with clinical mastitis caused by E. coli, microbiome dynamics 314 
in healthy quarters did not change over time (Fig. 5a). On the other hand, the relative 315 
abundance of Enterobacteriaceae decreased from study day 1 to 14 (62.6% vs. 9.7%), 316 
whereas the relative abundances of other families increased in mastitic quarters (Fig. 317 
5b). Changes in milk bacterial populations were not affected by intramammary therapy 318 
with ceftiofur hydrochloride (Fig. 5b). Treatment and the interaction between treatment 319 
and time did not affect the relative abundance of Enterobacteriaceae (Fig. 6a), or the 320 
Shannon (Fig. 1c) and Chao1 (Fig. S2 a) indexes in mastitic quarters infected by E. 321 
coli.  322 
Similar patterns were observed in cows with clinical mastitis caused by Klebsiella 323 
spp., as intramammary therapy did not impact the milk microbiome or the relative 324 
abundance of Enterobacteriaceae (Fig. S5 and S6). The only two cows diagnosed with 325 
clinical mastitis associated with Pseudomonas spp. presented an elevated abundance 326 
of Pseudomonadaceae on day 1 (44.3%), which was reduced until day 8 (3.3%) and 327 
then returned to initial values on day 14 (46.1%). Because both cows were assigned to 328 
receive intramammary infusion with ceftiofur hydrochloride, the effect of treatment on 329 
abundance of Pseudomonas spp. could not be assessed.  330 
Changes in the milk microbiome over time were not observed in cows affected by 331 
clinical mastitis associated with negative aerobic culture (Fig. 7a). Moreover, 332 
intramammary treatment with ceftiofur hydrochloride in these quarters did not affect the 333 
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milk microbiome (Fig. 7b) or the measures of microbial diversity and richness (Fig. 1d), 334 
(Fig. S2 b). 335 
Microbiome Changes Associated With Clinical Mastitis Cure on the Mastitic 336 
Quarters of Cows With Mastitis Caused by Escherichia coli 337 
In cows diagnosed with clinical mastitis caused by E. coli, microbiome dynamics 338 
in mastitic quarters exhibited remarkable changes over time. Quarters that experienced 339 
clinical cure by the end of the study period had significantly lower abundances of 340 
Enterobacteriaceae family members in both control (Fig. 6c) and treated animals (Fig. 341 
6e). Nevertheless, microbial diversity at diagnosis of clinical mastitis did not differ 342 
between quarters that eventually became cured or not (Fig. 6b). However, microbial 343 
diversity of quarters that eventually were cured showed increasing microbial diversities 344 
in both the control (Fig. 6d) and treated groups (Fig. 6f) relative to quarters that did not 345 
show bacteriological cure during the study period. Similar patterns were observed for 346 
bacteriological cure (Fig. S7). 347 
 348 
Multivariate Analysis of Microbiome data from Healthy and Mastitic Quarters 349 
Analysis of similarities revealed that mastitic quarters were significantly different 350 
from healthy quarters at the first day after diagnosis of clinical mastitis in cows with 351 
clinical mastitis associated with E. coli (Fig. 8a), and negative culture (Fig. 8b). A clear 352 
separation between mastitic and healthy quarters was observed in the principal 353 
coordinate analysis of Unifrac distances in animals with clinical mastitis associated with 354 
E. coli (Fig. 8a); however the same could not be observed in animals with mastitis 355 
associated with negative culture (Fig. 8b). At the end of the study, namely day 14 after 356 
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diagnosis of clinical mastitis, the microbiome of quarters that had been cured from 357 
clinical mastitis did not differ from the one of healthy quarters in either ANOSIM or 358 
Unifrac PCoA in cows previously identified with clinical mastitis associated with E. coli 359 
(Fig. 8e) nor in animals with clinical mastitis yielding negative aerobic culture (Fig. 8f). 360 
Interestingly, when the microbiome of quarters that remained with abnormal milk by the 361 
end of the study was included in the analysis, a significant difference could be observed 362 
in both ANOSIM and Unifrac PCoA on the microbiome of milk from cows identified with 363 
clinical mastitis associated with E. coli (Fig. 8c). No separation between mastitic, 364 
healthy, and cured quarters could be observed when the first three components of 365 
Unifrac PCoA were plotted in animals with mastitis associated with negative culture 366 
(Fig. 8d). 367 
 368 
DISCUSSION 369 
In an endeavor to better understand the effect of a third-generation 370 
cephalosporin (ceftiofur) in Gram-negative and culture-negative bovine mammary 371 
infections, we used high-throughput DNA sequencing to assess longitudinal changes in 372 
the microbiome of mastitic and healthy milk in a randomized clinical trial. Our data 373 
demonstrate that antimicrobial treatment did not significantly affect total bacterial load in 374 
the infected quarters by the end of the treatment period, nor was it able to increase the 375 
rate of pathogen clearance within the mammary gland. Moreover, this is the first study 376 
to document in depth the dynamics of the milk microbiota longitudinally using state-of-377 
the art technology. 378 
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Treatment with ceftiofur did not affect clinical or bacteriological cure and did not 379 
have long-lasting effects on the milk microbiome. Our results are in disagreement with 380 
those of Schukken et al. (2011) 34, who reported 38% bacteriological cure in non-treated 381 
cows and 73% bacteriological cure in treated animals. Their 5-day intramammary 382 
treatment regime with ceftiofur resulted in a significant increase in bacteriological cure, 383 
particularly in animals infected with E. coli, whereas our results demonstrate no 384 
difference between treated and untreated animals in this aspect. However, our results 385 
are in agreement with those of a landmark study conducted by Lago et al. (2011) 35,36, 386 
which demonstrated that selective antimicrobial treatment of mastitic cows can lead to a 387 
considerable reduction in antimicrobial use without any significant differences in days to 388 
clinical cure, bacteriological cure risk, new intramammary infection risk or treatment 389 
failure. In that study, cows diagnosed with mastitis associated with E. coli either 390 
received two intramammary doses of cephapirin sodium 12 hours apart or did not 391 
receive antimicrobial treatment. The investigators were not able to detect any 392 
differences between treated and untreated animals in either clinical or bacteriological 393 
cures. It is important to acknowledge that the treatment applied in that study utilized a 394 
first-generation cephalosporin, which has a lower effectiveness against Gram-negative 395 
pathogens compared to ceftiofur 16.  396 
Despite the observed effect of intramammary infusion of ceftiofur in reducing the 397 
total bacterial load measured by qPCR of the V4 region of the 16sRNA gene in the 398 
affected quarter on day 3, we failed to detect any differences between treated and 399 
untreated quarters at days 8 and 14 post diagnosis. Furthermore, our data revealed that 400 
ceftiofur therapy had no effect on total bacterial load 3 days after cessation of treatment. 401 
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We also assessed the longitudinal effect of antibiotic therapy on the relative abundance 402 
of the causal mastitis pathogens between treated and untreated cows; again, no 403 
differences were observed between the treatment and control groups. The observation 404 
that pathogen load was not affected by antimicrobial treatment is substantiated by a 405 
consistent decrease in the relative abundance of Enterobacteriaceae at 14 days post 406 
diagnosis in both treatment arms. Lastly, regardless of the treatment group, milk 407 
samples obtained on day 14 from all quarters deemed as mastitic on day 0 and that had 408 
normal milk on day 14 all presented a similar, more diverse bacterial profile, one 409 
remarkably comparable to that in healthy milk. Our data demonstrate that antimicrobial 410 
therapy does not improve cure rates for mastitis caused by E. coli, given the similar 411 
patterns of reduction in the percentage of pathogens over time in treated versus non-412 
treated animals, which is in line with the results of Leininger et al. (2003)37 and the 413 
recommendations of Suojala et al. (2013) 14. 414 
We have demonstrated how the microbiome of mastitic quarters associated with 415 
Gram-negative pathogens dynamically changes over time. More interestingly, quarters 416 
that were not cured by the end of the study period had diverging abundances of 417 
Enterobacteriaceae and microbial diversities over time when compared to mastitic 418 
quarters that became healthy by the end of the study period. Reduced bacterial diversity 419 
has also been reported in other studies comparing samples derived from healthy and 420 
diseased mammary environments 9,11,38. Although, most mastitis cases caused by E. 421 
coli are of an acute/peracute nature and have a high self-cure rate, chronic cases have 422 
been reported in the literature 39,40. Further research is needed to understand the host 423 
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and pathogen idiosyncrasies that are associated with the chronification of these E. coli-424 
related mastitis cases.  425 
Elucidating the milk microbiome has been a daunting task41, particularly in clinical 426 
mastitis with negative culture results 10. Various reasons could explain why a negative 427 
result might be obtained from a mastitic milk culture: the microorganisms associated 428 
with the infection might be shed intermittently; or the number of viable bacterial cells are 429 
small; finally, the cow’s immune system might have eliminated the pathogen, and the 430 
observation of abnormal milk could be a consequence of the inflammatory process that 431 
occurred during destruction of the pathogen 42. Nevertheless, mastitis has also been 432 
reported to be caused by mechanical or chemical injury, as well as by non-bacterial 433 
infectious agents such as viruses43 and yeasts44. Although infrequent, it is important to 434 
acknowledge that a portion of these culture negative mastitis cases can be result of a 435 
viral infection playing a role in clinical mastitis. In fact, the historical role of viruses in 436 
mastitis might have been underestimated, given that the practice of laboratory diagnosis 437 
of viruses in mastitis cases is unusual43. 438 
In our study, mastitic quarters yielding a negative aerobic result differed in 439 
bacterial load compared to their healthy counterparts. This is a very interesting finding, 440 
as we were not able to identify in the microbial profiles any specific bacterial family that 441 
could be associated with these mastitis cases. The identification of a higher bacterial 442 
load not linked to a specific group of pathogens might indicate that dysbiosis occurs not 443 
only with changes in the composition of the mammary microbiota, but also with a simple 444 
nonspecific increase of intramammary bacterial load, leading to clinical signs of mastitis. 445 
It is true that the number of 16S rRNA copies in the genome is variable, which can 446 
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impact bacterial community analysis45; however, the quantification of 16S rRNA gene 447 
has been proved to be useful as a proxy for estimating bacterial load46. In our study, 448 
mastitic quarters exhibited significantly lower microbial diversity upon diagnosis 449 
compared to healthy quarters, which could indicate that fewer microbes were 450 
dominating the milk microbiome. Our results are in line with those of Kuehn et al. (2013) 451 
10, who identified that the microbiome of mastitic quarters is less diverse than healthy 452 
ones in culture-negative mastitis cases. Recent work by Falentin et. al. (2016)47 has 453 
raised an interesting discussion when it comes to microbial diversity, dysbiosis and 454 
disease. The investigators demonstrated that animals presenting normal milk at 455 
sampling, but with different histories in regards of clinical and subclinical mastitis had 456 
remarkably different bacterial diversity, as well as an altered microbial profile far from an 457 
episode of clinical mastitis. Research is warranted to determine the relationship 458 
between changes of the mammary microbiota and timing of clinical mastitis, and 459 
elucidate if a shift in the microbial profile predisposes to clinical mastitis, or if an active 460 
colonization of a rather normal microbiome is to be held accountable for both the clinical 461 
episode and the lasting effect on the alteration of the milk microbiome. Koskinen et al. 462 
(2010) 48 evaluated the use of a pathogen-specific real-time PCR assay for identification 463 
of mastitis bacteria and reported that 76% of culture-negative clinical mastitis samples 464 
were positive for various mastitis pathogens, including members of the Streptococci, 465 
Staphylococci and Enterobacteriaceae families. However, it has previously been 466 
reported that such bacteria are found in the microbiome of healthy milk of both humans 467 
and cows 11,18,49. Although infrequent, mastitis caused by different species of 468 
Mycobacterium has been reported in bovines, alpacas and dogs 50-53. Mycobacterium is 469 
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often misidentified as a negative culture due to its slow growth characteristics and 470 
because it is a facultative anaerobic microbe 50,54. In our results, we observed a non-471 
significant increase in the relative abundance of Mycobacteriaceae in mastitic animals 472 
yielding negative aerobic culture results. Identifying which microorganisms are 473 
associated with culture-negative mastitis does not justify the use of antimicrobial 474 
treatment; however, it does shed light on the bacterial etiology of the disease, facilitating 475 
decision-making regarding mastitis prevention strategies. 476 
Differences in the microbiome of healthy and mastitic milk samples have also 477 
been reported for cows 9-11 and humans 18,38. However, a unique feature of the research 478 
presented here is that we used a controlled randomized clinical trial approach to 479 
longitudinally describe the differences between milk from mastitic mammary glands and 480 
from healthy ones and the impact of antibiotic therapy on the microbiome from the onset 481 
of disease until its resolution. To our knowledge, this is the first study to longitudinally 482 
evaluate the effect of antimicrobial therapy using the combination of quantitative PCR 483 
and next-generation DNA sequencing in dairy cows. Bovine milk, similarly to human 484 
milk, exhibits a complex and dynamic microbial ecology 9-11,18,38,55. Nevertheless, 485 
significant efforts have been recently undertaken using culture-independent techniques 486 
to evaluate the effects of antibiotic therapy in swine 56, horses 57, gorillas 58, and 487 
humans 59-63. 488 
Antimicrobial use in the food industry could potentially impact human health, 489 
warranting its judicious use 64,65. Ceftiofur is the only FDA-approved third-generation 490 
cephalosporin for use in food-producing animals and has been classified by the World 491 
Health Organization as one of the critically important antimicrobials for human medicine 492 
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66. In summary, our work corroborates the existing literature and also provides novel 493 
evidence that the use of intramammary ceftiofur therapy for the treatment of mild and 494 
moderate cases of E. coli-caused and culture-negative mastitis is ineffective. More 495 
importantly, it suggests that antimicrobial stewardship in food animals can be achieved 496 
in certain situations without compromising the health of the animals. Additionally, the 497 
combined use of quantitative PCR and sequencing of the 16s rRNA gene is an effective 498 
approach to evaluate the usefulness of antibiotic therapy. 499 
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Table 1. Effects of intramammary treatment with ceftiofur hydrochloride on clinical mastitis cure in lactating dairy cows 680 
 Clinical cure  Bacteriological cure1 
Parameter Control Ceftiofur P  Control Ceftiofur P 
 ----------------- % (n/n) -----------------   ----------------- % (n/n) -----------------  
Cure on day 10 and 14        
Gram negative 73.9 (17/23) 75.0 (18/24) 0.93  82.6 (19/23) 79.2 (19/24) 0.76 
Escherichia coli 75.0 (15/20) 70.0 (14/20) 0.72  85.0 (17/20) 80.0 (16/20) 0.67 
Klebsiella spp. 66.7 (2/3) 100.0 (2/2) 0.36  66.7 (2/3) 100.0 (2/2) 0.36 
Pseudomonas spp.2 --- 100.0 (2/2) ---  --- 50.0 (1/2) --- 
Negative culture3 76.5 (13/17) 81.3 (13/16) 0.73  NA NA NA 
Overall 75.0 (30/40) 77.5 (31/40) 0.79  82.6 (19/23) 79.2 (19/24) 1.00 
1 Based on standard laboratory culture methods for identification of milk pathogens. 681 
2 All cows diagnosed with Pseudomonas spp. by laboratory culture were assigned to the Ceftiofur group; thus, evaluation 682 
of treatment effect was not possible. 683 
3 Evaluation of bacteriological cure is not applicable to cows with negative culture. NA = non-applicable. 684 
  685 
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FIGURES 686 
FIG 1. Effect of clinical mastitis and intramammary treatment with ceftiofur hydrochloride 687 
(days 1-5) on the number of 16S rRNA gene copies in cows with clinical mastitis 688 
associated with Escherichia coli (a) or negative culture (c), and microbial diversity in 689 
cows with clinical mastitis associated with Escherichia coli (b) or negative culture (d). 690 
Bars represent standard error of the mean. Asterisks represent significant differences at 691 
α = 0.05 between groups within the same study day. (a) Mastitic-Control had a 692 
significantly greater bacterial load than Mastitic-Ceftiofur and healthy quarters on day 3. 693 
(c) On day 1, both mastitic quarters had a significantly greater bacterial load when 694 
compared to healthy quarters. On day 8: Mastitic-Control had a significantly greater 695 
bacterial load than Mastitic-Ceftiofur and healthy quarters. 696 
FIG 2. Relative abundance of phyla in quarters diagnosed with clinical mastitis (red 697 
bars) and healthy quarters (blue bars) according to identification of milk pathogens by 698 
laboratory culture. ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05, †P ≤ 0.10. Bars represent standard 699 
error of the mean. 700 
FIG 3. Comparison of the microbiome from quarters with clinical mastitis associated 701 
with Escherichia coli and healthy quarters (i.e. reference for calculation of fold change). 702 
Size of the circle is proportional to the overall prevalence of each family. Color of the 703 
circle is associated with effect size. The graph plots log fold change in 16S rRNA gene 704 
abundance in mastitic relative to healthy control quarters versus false discovery rate 705 
(FDR) logWorth (i.e. -log10P). P-values are adjusted for FDR. The dashed line 706 
represents the adjusted P-value = 0.01. 707 
FIG 4. Comparison of the microbiome from quarters with clinical mastitis associated 708 
with negative culture and healthy quarters (i.e. reference for calculation of fold change) 709 
on day 0. Size of the circle is proportional to the overall prevalence of each family. Color 710 
of the circle is associated with effect size. The graph plots log fold change in 16S rRNA 711 
gene abundance in mastitic relative to healthy control quarters versus false discovery 712 
rate (FDR) logWorth (i.e. -log10P). P-values are adjusted for FDR. The dashed line 713 
represents the adjusted P-value = 0.05. 714 
FIG 5. Effect of intramammary treatment with ceftiofur hydrochloride on relative 715 
abundance of the 25 most prevalent families in milk from quarters with clinical mastitis 716 
associated with Escherichia coli. Numbers indicate day after diagnosis of clinical 717 
mastitis. 718 
FIG 6. Effect of intramammary treatment with ceftiofur hydrochloride (day 1) or cure on 719 
the relative abundance of Enterobacteriaceae and Shannon diversity index in cows with 720 
clinical mastitis associated with Escherichia coli. (a) Effect of intramammary treatment 721 
with ceftiofur hydrochloride (day 1) on the relative abundance of Enterobacteriaceae in 722 
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cows with clinical mastitis associated with E. coli. Effect of eventual clinical cure on the 723 
relative abundance of Enterobacteriaceae in cows with clinical mastitis associated with 724 
E. coli on control cows (c) and treated cows (e). Effect of cure on the Shannon index in 725 
cows with clinical mastitis associated with E. coli (b), on control cows (d) and treated 726 
cows (f). Asterisks represent significant differences at α = 0.05 between groups within 727 
the same study day. 728 
FIG 7. Effect of intramammary treatment with ceftiofur hydrochloride on relative 729 
abundance of the 25 most prevalent families in milk from quarters with clinical mastitis 730 
associated with negative culture. Numbers indicate day after diagnosis of clinical 731 
mastitis. 732 
FIG 8. Principal coordinate analysis of weighted Unifrac distances and ANOSIM 733 
analysis comparing the microbiome data of samples from healthy and mastitic quarters 734 
on day 1 (a and b) and day 14 (c, d, e, and f). Samples from quarters with clinical 735 
mastitis associated with E coli are depicted in sections a, c and e. Samples from 736 
quarters with clinical mastitis associated with negative culture are shown in sections b, 737 
d, and f. 738 
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